Company: DVAX
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001029142-25-000071
Chunk: 237

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 237
---
,841,222 shares of common stock remain outstanding.For accounting purposes, the cash received from the unwind of the Capped Calls was recorded as an increase to additional paid-in capital within the condensed consolidated statements of stockholders’ equity.

8. Segment Reporting

We operate in one operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Our Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. The following table presents segment revenue, measures of our segment’s profit or loss, and significant segment expenses (in thousands):Three Months EndedMarch 31, 2025Three Months EndedMarch 31, 2024Total revenues$68,164 $50,790 Less (add) (1):Cost of sales - product13,769 10,966 Research and development19,377 13,528 Selling and marketing24,571 24,677 General and administrative23,107 19,388 Other segment items (2)83,439 (9,048)Segment net loss (3)$(96,099)$(8,721)(1)The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.(2)Other segment items includes the net of: bad debt expense, interest income, interest expense, sublease income, loss on debt extinguishment, other expenses, and Benefit from income taxes, as presented on the face of our condensed consolidated statements of operations.(3)Net loss is our reported measure of segment profit or loss.

20

Table of Contents

9. Revenue Recognition 

Disaggregation of RevenuesThe following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months EndedMarch 31, 2025Three Months EndedMarch 31, 2024 U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, net     HEPLISAV-B$64,959 $- $64,959 $46,699 $1,146 $47,845 Total product revenue, net64,959 - 64,959 46,699 1,146 47,845 Other revenue2,847 358 3,205 2,802 143 2,945